Home
Careers
Conferences
Directory
Drug Discovery
Genes
InDepth
Marketing
News
Reports
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
Virtual Pharma - the radical route to success
2.
Manufacturing in the Global Pharmaceuticals Industry Key drivers, company strategies and regulations (3rd Edition)
3.
The Global Vaccines Market 2008-2023
4.
Global Biotech Market Analysis and Forecasts, 2008-2023
5.
Ablation Technologies Worldwide Market, 2008-2017: Products, Technologies Markets, Companies and Opportunities
6.
Picture Archiving and Communications Systems (PACS)
7.
Microarray Markets
8.
Medical Nanotechnology Markets
9.
Contract Manufacturing Opportunities in High-Growth Medical Devices (Catheters, Pacemakers, LVADs, Hip and Knee Implants, Air Pathways, Syringes)
10.
Infusion Pump Markets (Large Volume, Ambulatory, Disposable, Syringe, and Specialty Infusion Pumps)
Best Sellers:
1.
BioNewsCast Press Release Distribution Service
2.
5th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, March 2008
3.
Peripheral Neuropathy and Neuropathic Pain, 2008
4.
Blood Glucose Testing and Diabetes Management Report
5.
The Global Antibacterials Market R&D Pipelines Market Analysis and Competitive Landscape
6.
Contract Research Annual Review 2008
7.
Good Manufacturing Practice (GMP) Course
8.
Good Clinical Practice I (GCP) course
The Antibacterial Drug Market Analysis 2008 to 2013
This brand new market analysis by visiongain examines the prospects for antibacterial drugs from 2008 to 2013, including sales forecasts for leading pharmaceutical products. The antibacterial market is large in terms of disease area as well as the different drug classes. However, this market is entering into a crucial period with many key products losing patent protection, facing heavy generic competition. In the light of this, including other factors, visiongain predicts this market to decline in revenues but which products will suffer most? How can you fight this generic competition? The antibacterial drug market generated revenues of $30274m in 2006 but what will it be in 2013?
The antibacterial market only contained one blockbuster drug in 2006, this being Johnson & Johnsons Levaquin. Visiongain predicts that there will be room for one more blockbuster drug as Levaquin will lose patent protection. This detailed report also highlights pipeline developments and important contemporary issues, especially commercial drivers and restraints.
This report will specifically analyse the world markets for the following classes of antibacterials:
Cephalosporins
Macrolides
Penicillins
Fluoroquinolones
Carbapenems
Miscellaneous.
The group 'miscellaneous' is an assorted group of antibacterials which includes the minor classes: the tetracyclines, aminoglycosides, glycopeptides and sulphonamides plus individual antibacterials such as Zyvox and Vancocin.
The Antibacterial Drug Market Analysis 2008 examines the market critically through a comprehensive review of available information. Sources include industrial databases, commercial news, published reports, economic research and consultation with experts. Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.
In particular, The Antibacterial Drug Market concentrates on the following essential aspects of the market:
Discussion of the current pharmaceutical market
Forecast of the worldwide pharmaceutical market from 2008-2013
Drivers and restraints facing the antibacterial drug market
Opportunities and threats facing the antibacterial drug market
Growth of the antibacterial drugs market between 2008-2013
Commercial prospects for the market-leading drugs, with sales forecasts from 2008-2013
Individual forecasts of the leading drug classes from 2008-2013
The potential of generics manufacturers to penetrate this market
Pipeline developments with blockbuster potential
Currently marketed drugs with blockbuster potential
Discussion of unmet therapeutic needs and relative advantages of products
Why you should buy this report:
To receive a comprehensive analysis of the prospects for antibacterial drugs from 2008-2013
To discover predicted revenues, growth rates and other key metrics for leading pharmaceutical treatments from 2008-2013
To determine key activities of leading companies
To discover hot pipeline developments and up-and-coming products
To determine the forces that influence the market for antibacterial drugs:
Competitive characteristics of the market
Drivers
Restraints
Strengths, weaknesses, opportunities and threats (SWOT analysis)
To find out where the market is heading - both technologically and commercially
- PRICING-
- Single use licence $2,995.00
- Departmental copies (this entitles up to 5 individual users in your department) of this report are available for only USD$5,995.00. This is not suitable for library usage.
- Allow your whole company to have access to this information for only USD$9,995.00.
Company-wide License allows your whole company access and intranet use on CD Rom and .pdf. Suitable for library storage and use.
- Does your company have over 2,500 employees? Have the whole company access this information for a special rate of only USD$13,995.00
March 2008
Table of Contents
Price
Department Licence 5 Users $5,995.00
Company-wide Intranet Licence $9,995.00
Company over 2500 employees $13,995.00
Single Use Licence $2995.00
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.